top
Search terms
Results 1 - 4 of 4 - ordered by :
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 586778 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes
Ehjcvp

Mean blood glucose changes in the placebo group were 0.6mmol/L (±3.1, P0.0002), 0.2 mmol/L (±2.7, P0.04), and 0.1 mmol/L (±3.0, P0.01) in the moderate, modest, and mild weight loss groups, ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Sadaf Kamil, Nicholas Finer, William Philip T James, Ian D. Caterson, Charlotte Andersson, Christian Torp-Pedersen

Date : 27/09/2016
Ehjcvp

Various studies have now raised hope for an additional protective effect of pharmacological DPP4 inhibition in vascular diseases. Besides GLP1, especially, the inhibition of SDF1 cleavage has been ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Friederike Remm, Wolfgang-Michael Franz, Christoph Brenner

Date : 01/07/2016